These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 23356886)

  • 1. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study.
    Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V
    Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.
    Lee JY; Kim N; Kim MS; Choi YJ; Lee JW; Yoon H; Shin CM; Park YS; Lee DH; Jung HC
    Dig Dis Sci; 2014 Jun; 59(6):1235-43. PubMed ID: 24599773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
    Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
    Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
    Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
    Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
    Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.